Key Points
- Heartflow insider Campbell Rogers sold 9,219 shares on May 18 at an average price of $28.34, worth about $261,266. The sale, made under a pre-arranged Rule 10b5-1 plan, reduced his direct holdings by 10.48%.
- Heartflow reported stronger-than-expected quarterly results, posting a loss of $0.16 per share versus the expected $0.24 loss. Revenue rose 41.3% year over year to $52.59 million.
- Wall Street remains broadly positive on HTFL, with analysts holding a consensus “Moderate Buy” rating and an average price target of $37.00, despite some recent target cuts.
Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) insider Campbell Rogers sold 9,219 shares of the company's stock in a transaction that occurred on Monday, May 18th. The shares were sold at an average price of $28.34, for a total value of $261,266.46. Following the transaction, the insider directly owned 78,731 shares of the company's stock, valued at $2,231,236.54. The trade was a 10.48% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Campbell Rogers also recently made the following trade(s):
- On Wednesday, April 1st, Campbell Rogers sold 64,533 shares of Heartflow stock. The stock was sold at an average price of $24.64, for a total value of $1,590,093.12.
- On Thursday, March 19th, Campbell Rogers sold 64,533 shares of Heartflow stock. The shares were sold at an average price of $25.69, for a total value of $1,657,852.77.
Heartflow Stock Up 2.9%
NASDAQ HTFL opened at $27.38 on Thursday. Heartflow, Inc. has a twelve month low of $20.13 and a twelve month high of $41.22. The firm has a market capitalization of $2.36 billion and a PE ratio of -8.80. The stock's 50 day moving average is $27.45 and its 200 day moving average is $28.57.
Heartflow (NASDAQ:HTFL - Get Free Report) last released its quarterly earnings results on Thursday, May 14th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.08. The firm had revenue of $52.59 million for the quarter. The business's revenue for the quarter was up 41.3% compared to the same quarter last year. On average, research analysts anticipate that Heartflow, Inc. will post -0.78 earnings per share for the current year.
Wall Street Analysts Forecast Growth
HTFL has been the topic of several recent research reports. JPMorgan Chase & Co. cut their price target on Heartflow from $40.00 to $35.00 and set an "overweight" rating on the stock in a research note on Thursday, March 19th. Wells Fargo & Company upped their price target on Heartflow from $35.00 to $37.00 and gave the stock an "overweight" rating in a research note on Friday, May 15th. Canaccord Genuity Group cut their price target on Heartflow from $43.00 to $37.00 and set a "buy" rating on the stock in a research note on Friday, May 15th. Finally, William Blair initiated coverage on Heartflow in a research note on Monday, May 4th. They issued an "outperform" rating on the stock. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $37.00.
Read Our Latest Report on HTFL
Institutional Trading of Heartflow
Institutional investors and hedge funds have recently modified their holdings of the business. Caitong International Asset Management Co. Ltd bought a new stake in shares of Heartflow in the 4th quarter worth $27,000. Russell Investments Group Ltd. bought a new stake in shares of Heartflow in the 4th quarter worth $45,000. Legal & General Group Plc bought a new stake in shares of Heartflow in the 3rd quarter worth $59,000. Strs Ohio bought a new stake in shares of Heartflow in the 4th quarter worth $99,000. Finally, Bessemer Group Inc. bought a new stake in shares of Heartflow in the 1st quarter worth $126,000.
Heartflow Company Profile
(
Get Free Report)
HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company's core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow's analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.
HeartFlow's cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
